Background: To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL)\nin achieving guideline-defined asthma control in Asian patients.\nMethods: A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use\ninto inhaled corticosteroid (ICS)-na�¯ve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and\nrandomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma\nor maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was\nthe proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total\nControl and adverse events. Asian and non-Asian patients were analysed separately.\nResults: In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus\n74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/\n104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three\nstrata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly\nand with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during\nPhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns\nwere identified.\nConclusions: A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally\nControlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian\npatients in S1 achieved Well-Controlled asthma in both treatment groups.
Loading....